BIIB: Felzartamab and lupus assets advance in late-stage trials, targeting major unmet needs
Meno di 1 minuto di lettura
The discussion highlighted a robust immunology pipeline, with felzartamab showing strong efficacy in late AMR and potential for durable disease control in IgA nephropathy and PMN. Multiple phase 3 and proof-of-concept studies are underway, and lupus programs are advancing with differentiated mechanisms and endpoints.
Based on Biogen Inc. [BIIB] Piper Sandler 37th Annual Healthcare Conference Audio Transcript — Dec. 3 2025
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr